Collateral for a security interest recorded Aug 25, 2022 (Midcap Financial Trust).
Term ended Jun 12, 2026 · High confidence
20-year base term ended Jan 19, 2026
Held by Rigel Pharmaceuticals, Inc.
Filed Nov 10, 2008 as application 12/268,218 · Granted Aug 2, 2011
Base term plus 144 days of patent term adjustment (USPTO delay)
Today
Term ended Jun 12, 2026
2006
2026
Clock starts
Jan 19, 2006
Jan 19, 2006
Term ended
Jun 12, 2026
Jun 12, 2026
Granted
Aug 2, 2011
Aug 2, 2011
base term
patent term adjustment
after the term ends
fee events
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
144
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 7,449,458, to Jun 12, 2026. The term already ends on or before that date, so the cap shortened nothing.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
13
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 144 days past its 20-year base term on prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. All three maintenance fees were paid, so no fee lapse ended it. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jan 19, 2006, when application 11/337,049, the earliest non-provisional in its chain, was filed (this one was filed Nov 10, 2008) | Jan 19, 2026 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +144 days, USPTO patent term adjustment record | Jun 12, 2026 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 7,449,458) | resolves to Jun 12, 2026, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | term ended | High confidence |
| Computed term end | The steps above, in order | Jun 12, 2026 | High confidence |
This family
| US 7,449,458 | In force Sep 2031 | Sep 2031 |
| US 7,538,108 | Term ended Mar 2026 | Mar 2026 |
| US 7,563,892 | Term ended Jun 2026 | Jun 2026 |
| US 7,989,448 | this patent Jun 2026 | Jun 2026 |
| US 8,211,888 | Term ended Jan 2026 | Jan 2026 |
| US 8,211,889 | Term ended Jan 2026 | Jan 2026 |
| US 8,476,263 | Term ended Jan 2026 | Jan 2026 |
| US 8,785,437 | Term ended no later than Jan 2026 | no later than Jan 2026 |
8 of 13 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jul 14, 2009 Reel 22948, frame 930 | Singh, Rajinder; Bhamidipati, Somasekhar; Masuda, Esteban | Rigel Pharmaceuticlas, Inc. | Assignment of Assignor's Interest |
| Aug 20, 2009 Reel 23132, frame 312 | Singh, Rajinder; Bhamidipati, Somasekhar; Masuda, Esteban | Rigel Pharmaceuticals, Inc. | Corrective Assignment to Correct the Assignee Name from Rigel Pharmaceuticlas, Inc. Previously Recorded on Reel 022948 Frame 0930. Assignor(S) Hereby Confirms the Correct Assignee Name Is Rigel Pharmaceuticals, Inc. |
| Jul 5, 2011 Reel 26543, frame 106 | Stella, Valentino J.; Sun, Thomas | Rigel Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Aug 25, 2022 Reel 61327, frame 712 | Rigel Pharmaceuticals, Inc. | Midcap Financial Trust | Security Interest |
| May 8, 2026 Reel 75576, frame 880 | Rigel Pharmaceuticals, Inc. | Midcap Funding IV Trust | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Note
The 144 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 7,449,458, ends no earlier than this term, so it caps nothing.
Citations
44
later US patents cite this one
That is top 25% of utility patents granted in 2011 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.